Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-02-18 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于召开2021年第一次临时股东大会的通知的更正暨提示性公告
AGM Information Classification · 95% confidence The document is a detailed notice and correction announcement regarding the convening of the 2021 first extraordinary general meeting (临时股东大会) of the company 健帆生物科技集团股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and proxy forms. The content focuses on the organization and procedural details of the shareholders' meeting rather than the meeting results or financial data. There is no financial report or earnings data presented. The document is not a report itself but a notice and correction about the meeting and voting process. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is over 5,000 characters and contains substantive meeting information, not just a brief announcement or link, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is AGM Information (AGM-R).
2021-02-18 Chinese
监事会关于2021年限制性股票激励计划激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 90% confidence The document is a public announcement by the supervisory board regarding the verification and public disclosure of the list of incentive recipients under the company's 2021 restricted stock incentive plan. It details the process of public notice, feedback, and the supervisory board's verification opinion on the eligibility of the incentive recipients. The content focuses on governance and compliance with stock incentive regulations rather than financial results, management changes, or capital updates. It is not a full report but an official announcement related to governance and incentive plan verification. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure that does not fit other specific categories like Remuneration Information or Management Reports.
2021-02-18 Chinese
《公司章程》修正案
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from the board of directors of 健帆生物科技集团股份有限公司 regarding amendments to the company's Articles of Association (公司章程). It details changes in registered capital and share capital due to repurchase and cancellation of restricted shares. The document mentions that the amendment requires shareholder approval at a general meeting. The content focuses on governance and capital structure changes but does not contain financial statements or detailed financial performance data. The document length is short (865 characters), and it is an announcement of changes to company bylaws and share capital, not a full report or financial statement. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding capital changes such as share repurchases and capital reduction.
2021-02-04 Chinese
公司章程
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of 健帆生物科技集团股份有限公司, detailing the company's organizational structure, shareholder rights, board responsibilities, share issuance, and governance rules. It references Chinese company law and securities law, and extensively covers governance practices, shareholder meetings, voting rights, and board composition. There is no indication that this is an announcement or a summary; it is a full governance document. This matches the definition of Governance Information (CGR), which includes reports detailing the company's internal rules, board structure, and governance practices.
2021-02-04 Chinese
国浩律师（深圳）事务所关于健帆生物科技集团股份有限公司2021年限制性股票激励计划（草案）之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a 2021 restricted stock incentive plan for a listed company,健帆生物科技集团股份有限公司. It extensively discusses the legal qualifications, plan details, stock grant conditions, performance targets, and compliance with relevant laws and regulations. The content focuses on the company's stock incentive plan, including the issuance of restricted stock to employees and management, and the legal framework governing this plan. This type of document is typically classified under Capital/Financing Update (CAP) because it relates to the company's equity incentive plan, which affects capital structure and financing arrangements. It is not an annual or interim financial report, audit report, or earnings release. It is not a regulatory filing or announcement of a report but a substantive legal opinion on a financing-related plan. Therefore, the appropriate classification is CAP with high confidence.
2021-02-04 Chinese
创业板上市公司股权激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a detailed compliance checklist related to a stock incentive plan for a listed company, including regulatory compliance, internal controls, performance assessment, and legal opinions. It does not contain financial statements or financial performance data. It is not an announcement or a brief summary but a compliance and regulatory self-assessment document. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive content rather than just a notice. The document is best classified under Regulatory Filings (RNS) as it is a regulatory compliance document related to stock incentive plans and does not fit other specific categories.
2021-02-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.